Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690532 · ClinicalTrials.gov registry record
Gut Permeability Assessment in Celiac and Gluten Sensitive Children
A clinical trial of Celiac Disease, sponsored by Mayo Clinic.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02690532: Completed study of Celiac Disease, sponsored by Mayo Clinic.
NCT02690532 is a study of Celiac Disease that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690532, a study of Celiac Disease, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar \& water solution), and are hoping to prove its effectiveness in a clinical setting.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02690532
The ClinicalTrials.gov registry entry for NCT02690532 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02690532 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02690532 about?
NCT02690532 is a clinical study titled "Gut Permeability Assessment in Celiac and Gluten Sensitive Children". This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar \& water solution), and are hoping to prove its effectiveness in a clinical setting.
What is the current status of trial NCT02690532?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-08-01.
What conditions does trial NCT02690532 study?
This clinical trial studies the following conditions: Celiac Disease.
Who is sponsoring clinical trial NCT02690532?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690532 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
RECRUITING
-
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
RECRUITING · Phase 1
-
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
RECRUITING
-
Immune Responses to Gluten
RECRUITING · NA
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.